Literature DB >> 21840285

Cancer incidence in southern Iran, 1998-2002: results of population-based cancer registry.

Seyed Masoom Masoompour1, Hooman Yarmohammadi, Abbas Rezaianzadeh, Kamran Bagheri Lankarani.   

Abstract

PURPOSE: The main aim of this study was to obtain population-based cancer incidence data for the entire population of Fars province in Iran, and to compare these rates with those obtained from a previous study in the same population ten years previously.
METHODS: Data were collected on all patients in major cities of Fars province who were diagnosed with cancer between 1998 and 2002. The data were computerized using SPSS (Chicago, IL) software, version 13.0, and MS EXCEL (Microsoft, Redmond, WA) software with Persian fonts. The results are presented as incidence rates of cases by site, sex, age, crude rates, and age-standardized rates per 100,000 person-years (ASRs), using the direct method of standardization to the world population.
RESULTS: During the 5-year study period, 8359 new cancer cases were registered. Diagnosis of cancer was based on histopathological criteria in 86.7%, clinical or radiological criteria in 9.4% and death certificate only in 3.9% of cases. According to the calculated ASRs, the 5 most frequent cancers in women were breast (13 per 100,000), stomach (4.4 per 100,000), lung and bronchus (2.9 per 100,000), uterus (2.7 per 100,000), and colon and rectum (2.6 per 100,000); and in men, the 5 most frequent types were stomach (9.2 per 100,000), bladder (6.8 per 100,000), lung and bronchus (6.3 per 100,000), lymphocytic leukemia (4.1 per 100,000), and skin melanoma (3.8 per 100,000). The ASR for all cancers in men was 64.5 per 100,000, and that for women was 55.5 per 100,000.
CONCLUSION: Considering the limitations of this study, our results should be taken as the minimum incidence rates of cancers in Fars province, southern Iran. Significant differences were observed between the two study periods. However, we most likely have underestimated the frequencies of some tumors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21840285     DOI: 10.1016/j.canep.2011.05.018

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  22 in total

1.  Bisphosphonates and colon cancer.

Authors:  K B Lankarani
Journal:  Osteoporos Int       Date:  2012-07-19       Impact factor: 4.507

2.  The Incidence of Hepatocellular Carcinoma in Iran from 1996 to 2016: a Systematic Review and Meta-analysis.

Authors:  Soheil Hassanipour; Majid Mohammadzadeh; Fariborz Mansour-Ghanaei; Mohammad Fathalipour; Farahnaz Joukar; Hamid Salehiniya; Elham Abdzadeh; Ali Akbar Samadani; Hossein-Ali Nikbakht; Morteza Arab-Zozani
Journal:  J Gastrointest Cancer       Date:  2019-06

3.  Increased P-35, EBI3 Transcripts and Other Treg Markers in Peripheral Blood Mononuclear Cells of Breast Cancer Patients with Different clinical Stages.

Authors:  Maryam Hamidinia; Mehri Ghafourian Boroujerdnia; Abdolhassan Talaiezadeh; Ghasem Solgi; Reyhaneh Roshani; Sara Iranprast; Ali Khodadadi
Journal:  Adv Pharm Bull       Date:  2015-06-01

4.  Incidence of cutaneous malignant melanoma in Iranian provinces and American states matched on ultraviolet radiation exposure: an ecologic study.

Authors:  Roxana Moslehi; Nur Zeinomar; Francis P Boscoe
Journal:  Environ Pollut       Date:  2017-12-21       Impact factor: 8.071

5.  Incidence of Esophageal Cancer in Iran, a Population-Based Study: 2001-2015.

Authors:  Rahmatollah Moradzadeh; Parvaneh Golmohammadi; Bahman Ghaitasi; Haidar Nadrian; Athareh Najafi
Journal:  J Gastrointest Cancer       Date:  2019-09

6.  Epidemiology and trend of cancer in Isfahan 2005-2010.

Authors:  Fariborz Mokarian; Mohammad Arash Ramezani; Kamal Heydari; Maryam Tabatabaeian; Hossein Tavazohi
Journal:  J Res Med Sci       Date:  2011-09       Impact factor: 1.852

7.  Data coverage of a cancer registry in southern Iran before and after implementation of a population-based reporting system: a 10-year trend study.

Authors:  Kamran Bagheri Lankarani; Zahra Khosravizadegan; Abbas Rezaianzadeh; Behnam Honarvar; Mohsen Moghadami; Hossein Faramarzi; Mojtaba Mahmoodi; Mahin Farahmand; Seyed Masoom Masoompour; Bahman Nazemzadegan
Journal:  BMC Health Serv Res       Date:  2013-05-06       Impact factor: 2.655

8.  Umbelliprenin is cytotoxic against QU-DB large cell lung cancer cell line but anti-proliferative against A549 adenocarcinoma cells.

Authors:  Narges Khaghanzadeh; Zahra Mojtahedi; Mohammad Ramezani; Nasrollah Erfani; Abbas Ghaderi
Journal:  Daru       Date:  2012-10-30       Impact factor: 3.117

9.  Cancer incidence in North West Algeria (Mascara) 2000-2010: results from a population-based cancer registry.

Authors:  Bachir Benarba; Boumedienne Meddah; Houria Hamdani
Journal:  EXCLI J       Date:  2014-06-23       Impact factor: 4.068

10.  Body Esteem and Self-examination in British Men and Women.

Authors:  Gayle Brewer; Anne M Dewhurst
Journal:  Int J Prev Med       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.